MedTrace Logo

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China

NCT03059641 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2020-02-05

No results posted yet for this study

Summary

To evaluate the concordance of sensitizing mutations detected between paired plasma and tissue samples; the correlation between the clonal status of sensitizing mutations and targeted therapy response; and the prognostic impact of the relative abundance of sensitizing / resistance mutations.

Conditions

  • Lung Neoplasms
  • Lung Cancer, Nonsmall Cell
  • Adenocarcinoma of Lung
  • Squamous Cell Lung Cancer

Sponsors & Collaborators

  • Shanghai Chest Hospital

    collaborator OTHER

  • Geneplus-Beijing Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Shun Lu, MD · Shanghai Chest Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-22
Primary Completion
2019-12-31
Completion
2020-01-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03059641 on ClinicalTrials.gov